ライフサイエンスコーパス: placenta growth factor

1 these findings, the VEGFR-1-specific ligand placenta growth factor-1 activated phosphatidylinositol

2 To determine the VEGF(165) and placenta growth factor 2 (PlGF-2)-binding sites of NRP1,

3 The neuropilin-1 ligand placenta growth factor-2 failed to reproduce the protect

4 ynamic biomarkers, such as changes in plasma placenta growth factor and sVEGFR2.

5 biomarkers fms-related tyrosine kinase 1 and placenta growth factor, and glomerular atrophy; urinary

6 nt with an Flt-1 neutralizing antibody or by placenta growth factor but not with an Flk-1 neutralizin

7 Placenta growth factor concentration was significantly l

8 By contrast, tissue levels of placenta growth factor decreased.

9 (GM-CSF), stromal derived factor 1alpha, and placenta growth factor], G-CSF and the G-CSF-induced Bv8

10 or, tumor necrosis factor receptors 1 and 2, placenta growth factor had an inverse association with M

11 Our studies show that placenta growth factor levels are high in SCD, and place

12 mically, cediranib increased plasma VEGF and placenta growth factor levels, and the number of circula

13 not detected in response to stimulation with placenta growth factor or an Flt-1-selective VEGF mutant

14 evels of vascular endothelial growth factor, placenta growth factor, or soluble endoglin as assessed

15 line of greater than 20% in plasma levels of placenta growth factor (P = .056), squamous cell carcino

16 upregulate several growth factors including placenta growth factor (PGF).

17 vestigate the in vivo angiogenic activity of placenta growth factor (PIGF) and its heterodimers with

18 This binding was efficiently competed by placenta growth factor (PIGF), a ligand reportedly speci

19 o vascular endothelial growth factor (VEGF), placenta growth factor (PIGF-1 and PIGF-2), or basic fib

20 Our studies showed that placenta growth factor (PlGF) activated monocytes and in

21 cessive production of the angiogenic protein placenta growth factor (PlGF) and high estimated pulmona

22 These proteins included, among others, Placenta Growth Factor (PLGF) and Vascular Endothelial G

23 ecently reported that treatment with an anti-placenta growth factor (PlGF) antibody inhibits metastas

24 We hypothesize that VEGF and placenta growth factor (PlGF) are dysregulated in preecl

25 Previous studies showed that high levels of placenta growth factor (PlGF) correlated with increased

26 , apoptosis, autophagy and emphysema-related placenta growth factor (PlGF) expressions.

27 The role of placenta growth factor (PlGF) in pathologic angiogenesis

28 reviously, we showed that elevated levels of placenta growth factor (PlGF) in SCA patients correlate

29 ascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) in the VEGF/PDGF gene fami

30 Placenta growth factor (PlGF) is a mitogen for endotheli

31 Placenta growth factor (PlGF) is a pro-inflammatory angi

32 Placenta growth factor (PlGF) is an additional ligand fo

33 Placenta growth factor (PlGF) is released by immature er

34 ammation, whereas blockade of either VEGF or placenta growth factor (PlGF) signaling did not affect t

35 Placenta growth factor (PlGF) stimulated robust angiogen

36 GF), soluble VEGF receptor 1 (sVEGFR-1), and placenta growth factor (PlGF) were measured by enzyme-li

37 We previously demonstrated that placenta growth factor (PlGF), an angiogenic factor prod

38 We found that erythroid cells produced placenta growth factor (PlGF), an angiogenic growth fact

39 We hypothesized that placenta growth factor (PlGF), an erythroblast-secreted

40 s vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), and platelet-derived endo

41 VEGF-B is closely related to VEGF-A and placenta growth factor (PlGF), but unlike VEGF-A, which

42 Placenta growth factor (PlGF), elaborated from erythroid

43 Placenta growth factor (PlGF), elaborated from erythroid

44 d that VEGF-A or VEGF-E, but not VEGF-B, nor placenta growth factor (PlGF), induces the phosphorylati

45 Placenta growth factor (PlGF), released at high levels b

46 previous studies show that higher levels of placenta growth factor (PlGF), secreted by erythroid pre

47 eviously showed that erythroid cells produce placenta growth factor (PlGF), which activates monocytes

48 ascular endothelial growth factor (VEGF) and placenta growth factor (PlGF).

49 binding to their ligands, including VEGF and placenta growth factor (PlGF).

50 Flt-1 has an alternative ligand, placenta growth factor (PlGF).

51 t the Escherichia coli expressed monomers of placenta growth factor (PLGF)129 and vascular endothelia

52 ot bind to VEGF121 or the smaller isoform of placenta growth factor (PlGF129), and show reduced, but

53 were evaluated after administration of PEDF, placenta growth factor (VEGF-R1 agonist), and VEGF-E (VE

54 Placenta growth factor, which binds to Flt-1/VEGF-R1 but

55 We found that placenta growth factor, which selectively activates VEGF